Federated Hermes’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Federated Hermes’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-516,589	Closed	-$55.4M	–	2261
2023 Q1	$55.4M	Sell	516,589 -5,812	-1%	-$669K	0.14%	178
2022 Q4	$57.5M	Buy	522,401 +202,267	+63%	+$13.1M	0.16%	163
2022 Q3	$18.9M	Buy	+320,134	New	+$14.6M	0.06%	396

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Federated Hermes's RXDX Position: Q2 2023 in Review

Federated Hermes sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 516,589 shares — an estimated $55.4M sold.

Federated Hermes first reported a position in RXDX in Q3 2022 and held it in 3 quarters. The position peaked at $57.5M in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Federated Hermes reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Federated Hermes sold 516,589 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $55.4M.
Federated Hermes first reported a position in Prometheus Biosciences, Inc. Common Stock in Q3 2022 and held it in 3 quarters.
Federated Hermes's Prometheus Biosciences, Inc. Common Stock position peaked at $57.5M in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Federated Hermes's 13F filing for Q2 2023, filed 14 Aug 2023.